Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 2
2006 1
2007 3
2008 5
2009 16
2010 30
2011 74
2012 91
2013 186
2014 268
2015 354
2016 462
2017 505
2018 705
2019 903
2020 1828
2021 2230
2022 734
Text availability
Article attribute
Article type
Publication date

Search Results

7,436 results
Results by year
Filters applied: . Clear all
Page 1
Drug repurposing: progress, challenges and recommendations.
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Pushpakom S, et al. Nat Rev Drug Discov. 2019 Jan;18(1):41-58. doi: 10.1038/nrd.2018.168. Epub 2018 Oct 12. Nat Rev Drug Discov. 2019. PMID: 30310233 Review.
Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compo …
Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' dr …
Artificial intelligence in COVID-19 drug repurposing.
Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Zhou Y, et al. Lancet Digit Health. 2020 Dec;2(12):e667-e676. doi: 10.1016/S2589-7500(20)30192-8. Epub 2020 Sep 18. Lancet Digit Health. 2020. PMID: 32984792 Free PMC article. Review.
Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. ...In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or
Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging dise
Drug repositioning and repurposing: terminology and definitions in literature.
Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Langedijk J, et al. Drug Discov Today. 2015 Aug;20(8):1027-34. doi: 10.1016/j.drudis.2015.05.001. Epub 2015 May 11. Drug Discov Today. 2015. PMID: 25975957 Review.
Drug repositioning and similar terms have been a trending topic in literature and represent novel drug development strategies. We analysed in a quantitative and qualitative manner how these terms were used and defined in the literature. In total, 217 articles
Drug repositioning and similar terms have been a trending topic in literature and represent novel drug development stra
Drug repurposing: a promising tool to accelerate the drug discovery process.
Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Parvathaneni V, et al. Drug Discov Today. 2019 Oct;24(10):2076-2085. doi: 10.1016/j.drudis.2019.06.014. Epub 2019 Jun 22. Drug Discov Today. 2019. PMID: 31238113 Review.
It is necessary to discover new strategies for reducing the drug discovery time frame. Today, drug repurposing has gained importance in identifying new therapeutic uses for already-available drugs. ...Numerous strategies to discover new indications for FDA-ap …
It is necessary to discover new strategies for reducing the drug discovery time frame. Today, drug repurposing has gain …
Drug repurposing for COVID-19: Approaches, challenges and promising candidates.
Ng YL, Salim CK, Chu JJH. Ng YL, et al. Pharmacol Ther. 2021 Dec;228:107930. doi: 10.1016/j.pharmthera.2021.107930. Epub 2021 Jun 23. Pharmacol Ther. 2021. PMID: 34174275 Free PMC article. Review.
Among other reasons, the exorbitant costs, high attrition rate and extensive periods of time from research to market approval are the primary contributing factors to the lag in recent traditional drug developmental activities. Due to these reasons, drug developers a …
Among other reasons, the exorbitant costs, high attrition rate and extensive periods of time from research to market approval are the primar …
Drug repurposing from the perspective of pharmaceutical companies.
Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D. Cha Y, et al. Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18. Br J Pharmacol. 2018. PMID: 28369768 Free PMC article. Review.
Drug repurposing holds the potential to bring medications with known safety profiles to new patient populations. Numerous examples exist for the identification of new indications for existing molecules, most stemming from serendipitous findings or focused recent eff
Drug repurposing holds the potential to bring medications with known safety profiles to new patient populations. Numerous exam
A review on drug repurposing applicable to COVID-19.
Dotolo S, Marabotti A, Facchiano A, Tagliaferri R. Dotolo S, et al. Brief Bioinform. 2021 Mar 22;22(2):726-741. doi: 10.1093/bib/bbaa288. Brief Bioinform. 2021. PMID: 33147623 Free PMC article. Review.
Drug repurposing involves the identification of new applications for existing drugs at a lower cost and in a shorter time. There are different computational drug-repurposing strategies and some of these approaches have been applied to the coronavirus d
Drug repurposing involves the identification of new applications for existing drugs at a lower cost and in a shorter time. The
Editorial: Drug Repurposing.
Pantziarka P, André N. Pantziarka P, et al. Front Med (Lausanne). 2019 Jul 3;6:154. doi: 10.3389/fmed.2019.00154. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31334237 Free PMC article. No abstract available.
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.
Vicenti I, Zazzi M, Saladini F. Vicenti I, et al. Expert Opin Ther Pat. 2021 Apr;31(4):325-337. doi: 10.1080/13543776.2021.1880568. Epub 2021 Mar 3. Expert Opin Ther Pat. 2021. PMID: 33475441 Free PMC article. Review.
RNA-dependent RNA-polymerase (RdRp), which has no counterpart in human cells, is an excellent target for drug development. Given the time-consuming process of drug development, repurposing drugs approved for other indications or at least successfully tested i …
RNA-dependent RNA-polymerase (RdRp), which has no counterpart in human cells, is an excellent target for drug development. Given the …
Drug Repurposing for Rare Diseases.
Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Roessler HI, et al. Trends Pharmacol Sci. 2021 Apr;42(4):255-267. doi: 10.1016/j.tips.2021.01.003. Epub 2021 Feb 6. Trends Pharmacol Sci. 2021. PMID: 33563480 Review.
Although drug repurposing is not novel, new strategies have been developed in recent years to do it in a systematic and rational way. Here, we review applied methodologies, recent accomplished progress, and the challenges associated in drug repurposing
Although drug repurposing is not novel, new strategies have been developed in recent years to do it in a systematic and ration …
7,436 results